BackNovo Nordisk Overview
Novo Nordisk - ADR

Novo Nordisk Target Price

See Novo Nordisk's analyst price targets ($45) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$37.53

Average Target Price

$44.6719% upside

3 analysts in the last 4 months

High: $47 | Low: $40

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-11Morgan StanleyThibault Boutherin$406.6% upsideOpen
2026-08-12Berenberg BankKerry Holford$4725.2% upsideOpen
2026-08-06BMO CapitalEvan Seigerman$4725.2% upsideOpen
2026-02-05BMO Capital$4519.9% upsideOpen
2026-01-26BMO CapitalEvan Seigerman$5751.9% upsideOpen
2025-12-10HSBC$5443.9% upsideOpen
2025-12-03Morgan StanleyThibault Boutherin$4211.9% upsideOpen
2025-11-25BMO CapitalEvan Seigerman$4622.6% upsideOpen
2025-10-14BMO CapitalEvan Seigerman$5546.5% upsideOpen
2025-10-01HSBC$7086.5% upsideOpen
2025-09-29Morgan Stanley$4725.2% upsideOpen
2025-07-31HSBC$5751.9% upsideOpen
2025-07-23Truist FinancialJailendra Singh$4827.9% upsideOpen
2024-10-17BMO CapitalEvan Seigerman$156315.7% upsideOpen
2024-09-11Cantor FitzgeraldLouise Chen$160326.3% upsideOpen
2024-08-08BMO CapitalEvan David Seigerman$160326.3% upsideOpen
2024-06-10Argus ResearchJasper Hellweg$160326.3% upsideOpen
2024-05-30Goldman SachsJames Quigley$156315.7% upsideOpen
2024-04-12BMO CapitalEvan David Seigerman$163334.3% upsideOpen

Novo Nordisk (NVO) FAQ

Novo Nordisk posts a target price of $45. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $45 for NVO means covering analysts, on average, see the stock 19.0% upside of $37.53 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for NVO's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Novo Nordisk's other metric pages and overview cover the third.

Judging Novo Nordisk against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $45 here, then scan peer and history charts to see if the gap is persistent.